Calderon Martinez Ernesto, Castillo Jaqueline L, Zachariah Saji Stephin, Stein Daniel, Khan Tayyaba J, Guardado Williams Rosa F, Munguía Irma D, Arruarana Victor Sebastian, Velasquez Karen
Digital Health, Universidad Nacional Autónoma de México, Mexico, MEX.
General Medicine, Universidad Autonoma de Guadalajara, Guadalajara, MEX.
Cureus. 2024 Jan 10;16(1):e52054. doi: 10.7759/cureus.52054. eCollection 2024 Jan.
Type 1 diabetes mellitus (T1DM), characterized by the autoimmune destruction of pancreatic beta cells and consequent insulin deficiency, leads to various complications. Management primarily focuses on optimal glycemic control through intensive insulin therapy, either via multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII) using insulin pumps, which offer flexibility and improved basal insulin delivery. Despite the benefits of insulin pumps, such as reduced hypoglycemia risk and better mealtime insulin management, they pose challenges such as complexity in site changes and potential ketoacidosis due to tubing issues. This systematic review adheres to PRISMA guidelines and compares CSII with MDI in children and adolescents with T1DM, concentrating on outcomes such as glycemic control measured with HbA1c and glucose levels. The review includes studies meeting stringent criteria, encompassing a broad range of methodologies and geographies. The findings of this meta-analysis indicate the differences in glycemic control with CSII compared to MDI. However, significant heterogeneity in results and methodological variations across studies necessitate cautious interpretation. The study underscores the potential of CSII in offering better control for some patients, supporting a more personalized approach to T1DM management. It highlights the need for further research to understand the long-term effects and to refine treatment protocols, considering the variations in healthcare systems, treatment approaches, and patient demographics globally.
1型糖尿病(T1DM)的特征是胰腺β细胞的自身免疫性破坏以及随之而来的胰岛素缺乏,会导致各种并发症。治疗主要侧重于通过强化胰岛素治疗实现最佳血糖控制,可采用每日多次注射(MDI)或使用胰岛素泵进行持续皮下胰岛素输注(CSII),后者具有灵活性并能改善基础胰岛素输送。尽管胰岛素泵有诸多益处,如降低低血糖风险和更好地管理餐时胰岛素,但也带来了一些挑战,如更换注射部位操作复杂以及因管路问题可能导致酮症酸中毒。本系统评价遵循PRISMA指南,比较了T1DM儿童和青少年中CSII与MDI的效果,重点关注通过糖化血红蛋白(HbA1c)和血糖水平衡量的血糖控制等结果。该评价纳入了符合严格标准的研究,涵盖了广泛的方法和地域。这项荟萃分析的结果表明,与MDI相比,CSII在血糖控制方面存在差异。然而,研究结果存在显著异质性且各研究方法存在差异,因此需要谨慎解读。该研究强调了CSII对某些患者提供更好控制的潜力,支持对T1DM管理采取更个性化的方法。它突出了进一步研究的必要性,以了解长期影响并完善治疗方案,同时考虑到全球医疗系统、治疗方法和患者人口统计学的差异。